London, United Kingdom – At the CARTCR Summit in London, Senior Scientist Venera Kuci Emruli from Strike Pharma presented the company’s work on non-viral in-vivo CAR-T engineering, highlighting the potential for scalable manufacturing, simplified production processes, and future clinical translation.

The presentation generated valuable discussions around the next generation of in-vivo cell therapy approaches and provided an opportunity to engage with researchers, clinicians, and industry leaders working at the forefront of the field.